MedTrace Logo

Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis

NCT07451665 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2026-03-05

No results posted yet for this study

Summary

This is a prospective, open-label, controlled, multiple centers, randonmized clinical trial. It compares the clinical efficacy and safety of vunakizumab ivarmacitinib and glucocorticoids in the treatment of active Takayasu's arteritis.

Conditions

  • Takayasu Arteritis (TAK)

Interventions

DRUG

Vanakizumab

Vanakizumab 240mg each 4 weeks taken subcutaneously with an additional injection at day 15

DRUG

Ivarmacitinib

Ivarmacitinib 8mg daily taken orally

DRUG

Prednisone

Prednisone taken daily according to preset tapering protocol

Sponsors & Collaborators

  • Chinese SLE Treatment And Research Group

    lead OTHER

Principal Investigators

  • Xinping TIAN, M.D. · Peking Union Medical College Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-01
Primary Completion
2029-03-31
Completion
2029-03-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07451665 on ClinicalTrials.gov